12 Best Global Stocks to Buy According to Hedge Funds

Page 2 of 12

11. Novartis AG (NYSE:NVS)

Number of Hedge Fund Holders: 33

Novartis AG (NYSE:NVS) manufactures pharmaceutical and consumer healthcare products. For the fiscal year 2024, net sales reached $50.3 billion, reflecting an 11% increase (12% at constant currency), driven primarily by a 14-percentage-point contribution from volume growth. In mid-December, BioAge and Novartis announced their partnership on the discovery of new therapeutic targets for the treatment of age-related diseases and conditions. Under this agreement, BioAge will receive $20 million as an upfront payment and will be able to receive up to $530 million in milestones. In February, The Wall Street Journal reported that Novartis CEO Vas Narasimhan was taking a highly selective approach toward potential acquisitions in the obesity treatment sector. The firm is actively scouting for next-generation obesity drug candidates to expand its portfolio and capitalize on emerging market opportunities.

Page 2 of 12